Displaying drugs 2251 - 2275 of 3402 in total
RRx-001
RRx-001 has been used in trials studying the treatment of Lymphomas, Brain Metastases, Cholangiocarcinoma, Colorectal Neoplasms, and Malignant Solid Tumor, among others.
Investigational
MK-0873
MK-0873 has been used in trials studying the treatment of Rheumatoid Arthritis.
Investigational
ONT-093
ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp). In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics.
Investigational
TMV-083
TMV-083 is an attenuated live virus COVID-19 vaccine candidate which employs the measles vaccine as a vector . It expresses a spike protein antigen from SARS-CoV-2 .
Investigational
ANX-005
Investigational
MRK-003
MRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. It is the preclinical analog of MK-0752, a drug in clinical development.
Investigational
Matched Iupac: … (1'R,3R,10'S)-5-(2,2,2-trifluoroethyl)-5'-[(1E)-3-[4-(trifluoromethyl)piperidin-1-yl]prop-1-en-1-yl]spiro …
SYD-003
Investigational
MRG-003
MRG-003 is a recombinant humanized anti-human epidermal growth factor receptor monoclonal antibody conjugated to monomethyl auristatin E.
Investigational
ACP-015
Investigational
SIG-001
SIG-001 is a cultured human retinal pigment epithelial cell line (ARPE-19) genetically modified with a non-viral vector to express B domain deleted human factor VIII protein, encapsulated within two-layer modified alginate spheres.
Investigational
RST-001
RST-001 is a non-replicating recombinant adeno-associated virus vector containing a fragment of the gene encoding channel rhodopsin-2 protein.
Investigational
NBL-015
Investigational
FCX-013
FCX-013 consists of human dermal fibroblasts genetically modified with a lentiviral vector expressing metalloproteinase-1 (MMP-1).
Investigational
AV-0113
AV-0113 consists of IL-12 secreting dendritic cells loaded with autologous tumor lysate.
Investigational
AVB-001
AVB-001 is an encapsulated, engineered human ARPE-19 cell line that constitutively expresses the native human IL-2 cytokine
Investigational
ISP-001
ISP-001 consists of sleeping beauty transposon-engineered autologous plasmablasts for expression and delivery of alpha-L-iduronidase.
Investigational
Pegtibatinase
Investigational
Hypericin
Hypericin is under investigation for the treatment of Cutaneous T-cell Lymphoma.
Investigational
Matched Iupac: … 5,7,11,18,22,24-hexahydroxy-13,16-dimethyloctacyclo[13.11.1.1^{2,10}.0^{3,8}.0^{4,25}.0^{19,27}.0^{21,26 ... }.0^{14,28}]octacosa-1(27),2(28),3,5,7,10,12,14,16,18,21,23,25-tridecaene-9,20-dione …
MIP-1095 I-131
MIP-1095 I-131 is under investigation in clinical trial NCT03030885 (Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)).
Investigational
Ulviprubart
Investigational
CRA_10655
Experimental
MF101
MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation. MF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal...
Investigational
AM103
AM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation. It is being developed by Amira.
Investigational
Fx-1006A
Fx-1006A is a small molecule compound with the potential to treat genetic disorders, such as familial amyloid cardiomyopathy (FAC) and familial amyloid polyneuropathy (FAP).
Investigational
ACTUS-101
Investigational
Displaying drugs 2251 - 2275 of 3402 in total